Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,276
archived clinical trials in
Pancreatic Cancer

A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Fresh Meadows, NY
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Fresh Meadows, NY
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
New York, NY
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Rochester, NY
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Sleepy Hollow, NY
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Canton, OH
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Cincinnati, OH
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Portland, OR
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Allentown, PA
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Allentown, PA
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Hershey, PA
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Hershey, PA
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Langhorne, PA
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Langhorne, PA
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Greenville, SC
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Chattanooga, TN
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Knoxville, TN
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Nashville, TN
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Dallas, TX
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Lubbock, TX
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Lubbock, TX
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
San Antonio, TX
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Temple, TX
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Temple, TX
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Falls Church, VA
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Falls Church, VA
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Newport News, VA
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Newport News, VA
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Seattle, WA
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Green Bay, WI
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Green Bay, WI
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
509
mi
from
Graz,
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
509
mi
from
Graz,
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Washington,
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Fort Myers, FL
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Saint Petersburg, FL
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Saint Louis Park, MN
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Call for Information (Investigational Site 0629)
mi
from
Harrison, NY
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Call for Information (Investigational Site 0629)
mi
from
Harrison, NY
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Rockville Centre, NY
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Fort Worth, TX
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Status: Enrolling
Updated:  1/22/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Status: Enrolling
Updated: 1/22/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Status: Enrolling
Updated:  1/22/2018
University of Colorado Hospital Anschutz Cancer Pavillion
mi
from
Aurora, CO
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Status: Enrolling
Updated: 1/22/2018
University of Colorado Hospital Anschutz Cancer Pavillion
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Status: Enrolling
Updated:  1/22/2018
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Status: Enrolling
Updated: 1/22/2018
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Status: Enrolling
Updated:  1/22/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Status: Enrolling
Updated: 1/22/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Status: Enrolling
Updated:  1/22/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Status: Enrolling
Updated: 1/22/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer: A Pilot Study
Status: Enrolling
Updated:  1/22/2018
University of Houston
mi
from
Houston, TX
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer: A Pilot Study
Status: Enrolling
Updated: 1/22/2018
University of Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer: A Pilot Study
Status: Enrolling
Updated:  1/22/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer: A Pilot Study
Status: Enrolling
Updated: 1/22/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Stool Testing for Pancreatic Cancer
Detection of Pancreatic Cancer and Pre-cancer by Stool DNA Testing: A Feasibility Study
Status: Enrolling
Updated:  2/6/2018
Columbia University Medical Center
mi
from
New York, NY
Stool Testing for Pancreatic Cancer
Detection of Pancreatic Cancer and Pre-cancer by Stool DNA Testing: A Feasibility Study
Status: Enrolling
Updated: 2/6/2018
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Frequency of Methods of Local Invasion of Pancreatic Adenocarcinoma
Frequency of Methods of Local Invasion of Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  2/6/2018
Columbia University Medical Center
mi
from
New York, NY
Frequency of Methods of Local Invasion of Pancreatic Adenocarcinoma
Frequency of Methods of Local Invasion of Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 2/6/2018
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Pancreatic Intraepithelial Neoplasia (PanIN) and the Association With Recurrence of Pancreatic Adenocarcinoma
Refining the Molecular Progression From Intraductal to Invasive Pancreatic Cancer: Correlating Genetic Profiles and Clinicopathological Phenotypes in Sporadic and Familial Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  2/6/2018
Columbia University Medical Center
mi
from
New York, NY
Pancreatic Intraepithelial Neoplasia (PanIN) and the Association With Recurrence of Pancreatic Adenocarcinoma
Refining the Molecular Progression From Intraductal to Invasive Pancreatic Cancer: Correlating Genetic Profiles and Clinicopathological Phenotypes in Sporadic and Familial Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 2/6/2018
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer
A Phase I Study of Stereotactic Body Radiation Therapy in Patients With Unresected Carcinoma of the Pancreas or Ampulla
Status: Enrolling
Updated:  2/6/2018
University of Chicago
mi
from
Chicago, IL
Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer
A Phase I Study of Stereotactic Body Radiation Therapy in Patients With Unresected Carcinoma of the Pancreas or Ampulla
Status: Enrolling
Updated: 2/6/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer
Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  2/20/2018
St John's Mercy Medical Center
mi
from
Saint Louis, MO
Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer
Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 2/20/2018
St John's Mercy Medical Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Pilot Project for Cardiopulmonary and Functional Evaluation in Patients With Pancreatic Cancer Associated Cachexia
Pilot Project for Cardiopulmonary and Functional Evaluation in Patients With Pancreatic Cancer Associated Cachexia
Status: Enrolling
Updated:  2/21/2018
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Pilot Project for Cardiopulmonary and Functional Evaluation in Patients With Pancreatic Cancer Associated Cachexia
Pilot Project for Cardiopulmonary and Functional Evaluation in Patients With Pancreatic Cancer Associated Cachexia
Status: Enrolling
Updated: 2/21/2018
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Pilot Project for Cardiopulmonary and Functional Evaluation in Patients With Pancreatic Cancer Associated Cachexia
Pilot Project for Cardiopulmonary and Functional Evaluation in Patients With Pancreatic Cancer Associated Cachexia
Status: Enrolling
Updated:  2/21/2018
Sidney and Lois Eskenazi Hospital
mi
from
Indianapolis, IN
Pilot Project for Cardiopulmonary and Functional Evaluation in Patients With Pancreatic Cancer Associated Cachexia
Pilot Project for Cardiopulmonary and Functional Evaluation in Patients With Pancreatic Cancer Associated Cachexia
Status: Enrolling
Updated: 2/21/2018
Sidney and Lois Eskenazi Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer
A Feasibility Study for Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  3/5/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer
A Feasibility Study for Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 3/5/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  3/19/2018
Levine Cancer Institute-Albemarle
mi
from
Albemarle, NC
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 3/19/2018
Levine Cancer Institute-Albemarle
mi
from
Albemarle, NC
Click here to add this to my saved trials
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  3/19/2018
Levine Cancer Institute-South Tryon
mi
from
Charlotte, NC
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 3/19/2018
Levine Cancer Institute-South Tryon
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  3/19/2018
Levine Cancer Institute
mi
from
Charlotte, NC
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 3/19/2018
Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  3/19/2018
Levine Cancer Institute - Pineville
mi
from
Charlotte, NC
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 3/19/2018
Levine Cancer Institute - Pineville
mi
from
Charlotte, NC
Click here to add this to my saved trials